Search 

Scendea is a leading product development and regulatory consulting practice serving the pharmaceutical and biotechnology industry. We are committed problem solvers, redefining the meaning of customer service, with a focus on reducing time-to-market and minimising development costs.

A combination of scientific excellence, industry experience and a collaborative approach enable us to deliver high-quality innovative solutions, which allow our clients to succeed.

Our international team offers strategic and operational support in the fields of quality/CMC, non-clinical/toxicology, clinical/medical and regulatory, which guide products efficiently from early development to marketing approval.

At Scottish Development International (SDI) we’re all about discovery: helping ambitious businesses like yours discover an exciting new chapter in Scotland. We’re here to help you discover new business opportunities, markets, ventures and people. And, most importantly, a pathway to success. How about discovering more about your business you never dreamed possible? From tech to fintech to chemical science and digital technology, we’ve helped over 5135 inward investors to realise their ambitions in Scotland. We’ll connect you with the right people. In the right place. And at the right time.

SEKISUI Diagnostics, a global provider of innovative medical diagnostics to physicians and laboratories, has been committed to improving the lives of patients for over 30 years. We continue to invest in new diagnostic products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems. We are a leading provider of rapid tests in the U.S., and high throughput coagulation systems in Japan. We develop, manufacture, and supply over 1.7 billion tests each year to the global healthcare market through direct sales, our commercial distribution networks and our partners.

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence’s proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and
SLN124 to address beta-thalassaemia and myelodysplastic syndrome. Silence is also developing a C3 targeting programme, SLN500, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases. Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda.